aIt is hard to find a way out when you use other two person's logic in one paragraph 当您在一段时,使用其他二人逻辑发现出口是坚硬的[translate] aSD uPdate SD 更新[translate] aAppraising iniparib, the PARP inhibitor that never was--what must we learn? 评估 iniparib, PARP 抑制剂那没有是 ...
In this study, we provided a safety signal that haemorrhage-related adverse events should be monitored for when using niraparib. However, larger and more robust post-market safety studies are needed to improve the quality of this evidence.Shiyan Wang...
AML and MDS associated with PARP inhibitor treatment of ovarian cancer 2023, Gynecologic Oncology Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer 2024, International Journal of Molecular Sciences Poly(ADP-...
Although the use of PARP inhibitors is a huge step forward, it is apparent that patients, both with and without BRCA-mutant ovarian cancer, will eventually become resistant to PARP inhibitors. Therefore, novel combination therapies may enhance PARP inhibitor efficacy and overcome resistance mechanisms...
ahealth is for a long time. 健康长期是。[translate] aAppraising iniparib, the PARP inhibitor that never was--what must we learn? 评估 iniparib, PARP 抑制剂那没有是 -- 我们必须学习什么?[translate] aAll online AOS and IV payments are processed by the Department of Treasury through the Immi...
According to Leonard, “It’s hard to break away from R-CHOP-21, given that for two-thirds of the patients, it does the job.” Epratuzumab, bortezomib, lenalidomide, enzastaurin, and radioimmunotherapies are just a few of the novel agents being evaluated in combination with R-CHOP. The ...
Kinase genotype does not factor into overall survival once a GIST becomes metastatic. Thus, a KIT or PDGFRA mutation may set the initial course of a GIST, but the prognosis at the time of clinical presentation is S7 Modern Pathology (2014) 27, S1–S16 GISTs: what do we know now? S8 ...
Other nonselective PDE inhibitor used in the clinical trials is lisofylline. In a small group of septic patients, lisofylline reduced an ARDS-induced increase in the ratio of serum free fatty acids (i.e., the ratio of C18 unsaturated fatty acids linoleate and oleate to fully saturated palmi...
Although not alluded to in these articles, a novel cancer therapeutic strategy which does not take into account the responses outlined in Section 2, namely, the key roles played by apoptotic/dormant cancer cells in resistance and relapse, and overlooks intratumor heterogeneity which encompasses cancer...
We know at least one clinically relevant mechanism of PARP inhibitor resistance: the reversion of BRCA function by secondary mutations. Nevertheless, it is also clear that this mechanism does not explain all cases of resistance. At the moment, we only have a poor understanding of BRCA reversion-...